Dear colleagues,

Recent changes in marijuana prohibition laws across many regions in the world are resulting in increasing exposure to a wide variety of commercially available pharmaceutical and recreational products derived from the Cannabis plant. Whole dried Cannabis flower is among the most frequently used type of product, yet there remains a dearth of scientific research on the risks and benefits of using common and commercially available Cannabis flower and associated retail products. We are seeking research that can elucidate the medicinal applications and potential risks of consuming Cannabis flower and its derivatives for therapeutic purposes.

This Special Issue aims to provide a collective body of research specifically focused on the benefits and risks of conventional consumption of the Cannabis plant, rather than synthetic analogues and formulates commonly used in clinical trials. We are interested in both experimental and observational research designs, which are particularly useful for measuring the real-world effects of consuming the wide range of available plant strains and plant-derived products, which typically vary from batch-to-batch in their chemotypic properties due to the heterogenetic nature of all phytomedicines, including the Cannabis plant.

Furthermore, there is also a need for a better understanding of how effects from Cannabis consumption vary by individual or subgroup (e.g., across biological, demographic, or health conditions) in order to guide more personalized therapeutic treatments.

We are interested in scientific contributions from all fields of Cannabis research. We are particularly interested in researchers measuring the effects of consuming the natural Cannabis plant and derived products.

Topics of interest include:

• Cannabis use and pain;
• Cannabis use and mental health;
• Cannabis use pharmacodynamics;
• Cannabis use and cancer;
• Cannabis use and general health;
• Cannabis use and chronic illness;
• Cannabis use and general well-being;
• Individual differences in Cannabis effects;
• Benefits and risks of commercially available Cannabis products.

Dr. Jacob M. Vigil
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Cannabis
• health
• well-being
• chronic illness
• Cannabis research